FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Dirk Strumberg

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Phenomena

Phosphorylation

Living Beings

Clusia

Co-author Network

Publications

TOP 3
Beate Schultheis; Gerhard Kummer; Dirk Strumberg
Sarcomatoid non-small cell lung cancer responding to sunitinib.
David Díaz-Carballo; Sebastian Gustmann; Jacqueline Klein; Bastian Kohl; Ali Nazif; Raphael Stoll; Ali Haydar Acikelli; Walter Bardenheuer; Ulrike Dembinski; King Tou Yip; Dirk Strumberg
Multi-targeted polycyclic polyprenylated acylphloroglucinols are major constituents of Cuban propolis and contributors to its anticancer activity.
Ali Haydar Acikelli; Walter Bardenheuer; Ulrike Dembinski; Sebastian Gustmann; Jacqueline Klein; Bastian Kohl; Ali Nazif; Raphael Stoll; Dirk Strumberg; King Tou Yip; David Díaz-Carballo
Flavonoids isolated from Caribbean propolis show cytotoxic activity in human cancer cell lines.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Dirk Strumberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Beate Schultheis; Gerhard Kummer; Dirk Strumberg
Sarcomatoid non-small cell lung cancer responding to sunitinib.
International journal of clinical pharmacology and therapeutics 2013;51(1):87-8.
2013: David Díaz-Carballo; Sebastian Gustmann; Jacqueline Klein; Bastian Kohl; Ali Nazif; Raphael Stoll; Ali Haydar Acikelli; Walter Bardenheuer; Ulrike Dembinski; King Tou Yip; Dirk Strumberg
Multi-targeted polycyclic polyprenylated acylphloroglucinols are major constituents of Cuban propolis and contributors to its anticancer activity.
International journal of clinical pharmacology and therapeutics 2013;51(1):54-5.
2013: Ali Haydar Acikelli; Walter Bardenheuer; Ulrike Dembinski; Sebastian Gustmann; Jacqueline Klein; Bastian Kohl; Ali Nazif; Raphael Stoll; Dirk Strumberg; King Tou Yip; David Díaz-Carballo
Flavonoids isolated from Caribbean propolis show cytotoxic activity in human cancer cell lines.
International journal of clinical pharmacology and therapeutics 2013;51(1):51-3.
2012: David Díaz-Carballo; Suleyman Ergun; Sebastian Gustmann; Holger Jastrow; Ali Haydar Acikelli; Walter Bardenheuer; Helmut Buehler; Dirk Strumberg
7-epi-nemorosone from Clusia rosea induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells.
Phytomedicine : international journal of phytotherapy and phytopharmacology 2012;19(14):1298-306.
2012: Tanja Trarbach; Kathryn H Brown; Wilfried E E Eberhardt; Thomas Gauler; Stephanie Le Scouiller; Marcelo Marotti; Vesile Schneider; Beate Schultheis; Dirk Strumberg; Joachim Drevs
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Investigational new drugs 2012;30(5):1962-71.
2012: K Mross; Gerd Munzert; R M Schmid; J Schutte; Dirk Strumberg; W E Aulitzky; C Dittrich; F Fleischer; S Hollerbach; M Merger; Max E Scheulen
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.
British journal of cancer 2012;107(2):280-6.
2012: Dirk Strumberg; Beate Schultheis
Regorafenib for cancer.
Expert opinion on investigational drugs 2012;21(6):879-89.
2012: Beate Schultheis; Paul Scigalla; Dirk Strumberg; Jochen Schuette; Lothar Bergmann; Ullrich Graeven; Axel-Rainer Hanauske; Rainer Lipp; K Saito; Max E Scheulen
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Investigational new drugs 2012;30(3):1184-92.
2012: Dirk Strumberg; D Reuter; Max E Scheulen; Beate Schultheis; F Bach; L Edler; R A Hilger; J Krauss; F Lordick; N Marschner; K Mross
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
Investigational new drugs 2012;30(3):1138-43.
2012: Dirk Strumberg; Heike Richly; Max E Scheulen; B Schultheis; O Boix; Martin Büchert; O Christensen; A Frost; R Heinig; M Jeffers; K Mross
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
British journal of cancer 2012;106(11):1722-7.
2012: Max E Scheulen; Ralf A Hilger; Bastian Mende; Kaku Saito; Christopher Zergebel; Dirk Strumberg
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2012;69(3):753-61.
2012: Dirk Strumberg
Sorafenib for the treatment of renal cancer.
Expert opinion on pharmacotherapy 2012;13(3):407-19.
2012: Michael Untch; Gunter von Minckwitz; Joachim Bischoff; Jens-Uwe Blohmer; Holger Eidtmann; Peter A Fasching; Bernd Gerber; Claus Hanusch; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Rolf Kreienberg; Thorsten Kühn; Sibylle Loibl; Valentina Nekljudova; Mahdi Rezai; Dirk Strumberg; Hans Tesch
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
The lancet oncology 2012;13(2):135-44.
2012: B Schultheis; Erich Brendel; Martin Kornacker; G Kummer; C Xia; M Zeth; Dirk Strumberg
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Cancer chemotherapy and pharmacology 2012;69(2):333-9.
2011: Klaus Mross; Prabhu Rajagopalan; Max E Scheulen; Beate Schultheiss; Dirk Strumberg; Heinz Delesen; Ulrike Fasol; Annette Frost; Jörn Krätzschmer; Jürgen Krauss; Martin Büchert; Olaf Christensen
Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.
Vascular cell 2011;3():16.
2011: Andreas Hinkel; Dirk Strumberg; Joachim Noldus; Jürgen Pannek
Observation of de novo bladder dysfunction under treatment with Her2-neu antibodies.
Urologia internationalis 2011;86(1):80-4.
2010: Birgitta Schlüter; Roswitha Gerhards; Dirk Strumberg; Rudolf Voigtmann
Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.
Journal of cancer research and clinical oncology 2010;136(9):1389-400.
2010: Hartmut Kirchner; Dirk Strumberg; Amit Bahl; Friedrich Overkamp
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.
Expert review of anticancer therapy 2010;10(4):585-96.
2008: Dirk Strumberg
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3469-71; author reply 2471.
2007: Simone Steinbild; Klaus Mross; Annette Frost; Rudolf Morant; Silke Gillessen; Christian Dittrich; Dirk Strumberg; A Hochhaus; Axel R Hanauske; L Edler; Iris Burkholder; Max E Scheulen
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
British journal of cancer 2007;97(11):1480-5.
2007: Dirk Strumberg; jeffrey clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
The oncologist 2007;12(4):426-37.
2007: Heinz-Josef Lenz; Fa-Chyi Lee; Daniel G Haller; Deepti Singh; Al B Benson; Dirk Strumberg; Ronald Yanagihara; James C Yao; Alexandria Phan; Jaffer A Ajani
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
Cancer 2007;109(1):33-40.
2006: S Seeber; Dirk Strumberg
[Metastases with CUP syndrome].
Der Urologe. Ausg. A 2006;45(5):614-9.
2006: Heike Richly; B F Henning; Petra Kupsch; K Passarge; M Grubert; Ralf A Hilger; Olaf Christensen; Erich Brendel; Brian Schwartz; M Ludwig; C Flashar; Rudolf Voigtmann; Max E Scheulen; Siegfried Seeber; Dirk Strumberg
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(5):866-73.
2006: Dirk Strumberg; Ahmad Awada; Hal Hirte; jeffrey clark; Siegfried Seeber; P Piccart; E Hofstra; Dimitris Voliotis; Olaf Christensen; A Brueckner; Brian Schwartz
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
European journal of cancer (Oxford, England : 1990) 2006;42(4):548-56.
2006: Jaffer A Ajani; Fa-Chyi Lee; Deepti A Singh; Daniel G Haller; Heinz-Josef Lenz; Al B Benson; Ronald Yanagihara; Alexandria Phan; James C Yao; Dirk Strumberg
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(4):663-7.
2005: Dirk Strumberg
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Drugs of today (Barcelona, Spain : 1998) 2005;41(12):773-84.
2005: Ralf A Hilger; Heike Richly; M Grubert; Carsten Oberhoff; Dirk Strumberg; Max E Scheulen; Siegfried Seeber
Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil.
International journal of clinical pharmacology and therapeutics 2005;43(12):588-9.
2005: Petra Kupsch; Bernhard F Henning; Katrin Passarge; Heike Richly; Katrin Wiesemann; Ralf A Hilger; Max E Scheulen; Olaf Christensen; Erich Brendel; Brian Schwartz; Elke Hofstra; Rudolf Voigtmann; Siegfried Seeber; Dirk Strumberg
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Clinical colorectal cancer 2005;5(3):188-96.
2005: Alexander Schmittel; Max E Scheulen; Nikolaos E Bechrakis; Dirk Strumberg; Joachim Baumgart; Norbert Bornfeld; Michael H Foerster; Eckhard Thiel; Ulrich Keilholz
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Melanoma research 2005;15(3):205-7.
2005: Ahmad Awada; Alain Hendlisz; Thierry Gil; S Bartholomeus; M Mano; Dominique de Valeriola; Dirk Strumberg; Erich Brendel; Claus G Haase; Brian Schwartz; Martine Piccart
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
British journal of cancer 2005;92(10):1855-61.
2005: C C P Verstappen; Susanne Koeppen; Jan J Heimans; P C Huijgens; Max E Scheulen; Dirk Strumberg; B Kiburg; Tjeerd J Postma
Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.
Neurology 2005;64(6):1076-7.
2005: Dirk Strumberg; Heike Richly; Ralf A Hilger; Norbert Schleucher; Sonke Korfee; Mitra Tewes; Markus Faghih; Erich Brendel; Dimitris Voliotis; Claus G Haase; Brian Schwartz; Ahmad Awada; Rudolf Voigtmann; Max E Scheulen; Siegfried Seeber
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(5):965-72.
2005: Dirk Strumberg; Siegfried Seeber
Raf kinase inhibitors in oncology.
Onkologie 2005;28(2):101-7.
2005: Martina Heim; Mariam Scharifi; Jochen Zisowsky; Ulrich Jaehde; Dimitris Voliotis; Siegfried Seeber; Dirk Strumberg
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Anti-cancer drugs 2005;16(2):129-36.
2004: Thomas Gruger; John L. Nitiss; Anthony Maxwell; E Lynn Zechiedrich; Peter Heisig; Siegfried Seeber; Yves Pommier; Dirk Strumberg
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
Antimicrobial agents and chemotherapy 2004;48(12):4495-504.
2004: Martina Heim; Ralf A Hilger; S Kredtke; D Thyssen; F Bach; Dirk Strumberg
Improved viability of human tumor samples in a new oxygen-enriched solution.
International journal of clinical pharmacology and therapeutics 2004;42(11):659-60.
2004: Ralf A Hilger; Joachim Baumgart; Max E Scheulen; Rudolf Trenschel; Dirk Strumberg; Siegfried Seeber; Dietrich W Beelen
Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation.
International journal of clinical pharmacology and therapeutics 2004;42(11):654-5.
2004: Heike Richly; Petra Kupsch; K Passage; M Grubert; Ralf A Hilger; Rudolf Voigtmann; Brian Schwartz; Erich Brendel; Olaf Christensen; Claus G Haase; Dirk Strumberg
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
International journal of clinical pharmacology and therapeutics 2004;42(11):650-1.
2004: Ralf A Hilger; S Kredtke; Max E Scheulen; Siegfried Seeber; Dirk Strumberg
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
International journal of clinical pharmacology and therapeutics 2004;42(11):648-9.
2004: Dirk Strumberg; H Boeing; Max E Scheulen; H Förster; S Seeber
[Nutrition, lifestyle and cancer: strategies for primary prevention].
Deutsche medizinische Wochenschrift (1946) 2004;129(36):1877-82.
2004: Klaus Mross; Heike Richly; Norbert Schleucher; Sonke Korfee; Mitra Tewes; Max E Scheulen; Siegfried Seeber; Thomas Beinert; Markus Schweigert; U Sauer; Clemens Unger; Dirk Behringer; Erich Brendel; Claus G Haase; Dimitris Voliotis; Dirk Strumberg
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1284-94.
2004: Susanne Koeppen; C C P Verstappen; R Körte; Max E Scheulen; Dirk Strumberg; Tjeerd J Postma; Jan J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; Hans-Christoph Diener
Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.
Journal of cancer research and clinical oncology 2004;130(3):153-60.
2003: D Díaz-Carballo; Siegfried Seeber; Dirk Strumberg; Ralf A Hilger
Novel antitumoral compound isolated from Clusia rosea.
International journal of clinical pharmacology and therapeutics 2003;41(12):622-3.
2003: Heike Richly; Petra Kupsch; K Passage; M Grubert; Ralf A Hilger; S Kredtke; Dimitris Voliotis; Max E Scheulen; Siegfried Seeber; Dirk Strumberg
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
International journal of clinical pharmacology and therapeutics 2003;41(12):620-1.
2003: Martina Heim; M Sharifi; Ralf A Hilger; Max E Scheulen; Siegfried Seeber; Dirk Strumberg
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
International journal of clinical pharmacology and therapeutics 2003;41(12):616-7.
2003: Ralf A Hilger; D Díaz-Carballo; S Bauer; S Kredtke; Max E Scheulen; Siegfried Seeber; Dirk Strumberg
Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters?
International journal of clinical pharmacology and therapeutics 2003;41(12):614-5.
2002: Nouri Neamati; Zhaiwei Lin; Rajeshri G Karki; Ann H Orr; Kiriana Cowansage; Dirk Strumberg; Godwin C G Pais; Johannes H Voigt; Marc C Nicklaus; Heather E Winslow; He Zhao; Jim A Turpin; Jizu Yi; Anna Marie Skalka; Terrence R Burke; Yves Pommier
Metal-dependent inhibition of HIV-1 integrase.
Journal of medicinal chemistry 2002;45(26):5661-70.
2002: Ralf A Hilger; Max E Scheulen; Dirk Strumberg
The Ras-Raf-MEK-ERK pathway in the treatment of cancer.
Onkologie 2002;25(6):511-8.
2002: Dirk Strumberg; Dimitris Voliotis; J G Moeller; Ralf A Hilger; Heike Richly; S Kredtke; C Beling; Max E Scheulen; Siegfried Seeber
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.
International journal of clinical pharmacology and therapeutics 2002;40(12):580-1.
2002: Ralf A Hilger; S Kredke; D Hedley; J G Moeller; R J Bauer; Werner Stellberg; Siegfried Seeber; Max E Scheulen; Dirk Strumberg
ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.
International journal of clinical pharmacology and therapeutics 2002;40(12):567-8.
2002: Dirk Strumberg; John L. Nitiss; Jiaowang Dong; Jerrylaine Walker; Marc C Nicklaus; Kurt W Kohn; Jonathan G Heddle; Anthony Maxwell; Siegfried Seeber; Yves Pommier
Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Antimicrobial agents and chemotherapy 2002;46(9):2735-46.
2002: Dirk Strumberg; S Brügge; MW Korn; Susanne Koeppen; J Ranft; G Scheiber; Christoph Reiners; C Möckel; Siegfried Seeber; Max E Scheulen
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(2):229-36.
2000: Dirk Strumberg; Andre A Pilon; M Smith; Robert Hickey; Linda H Malkas; Yves Pommier
Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.
Molecular and cellular biology 2000;20(11):3977-87.
1999: Dirk Strumberg; John L. Nitiss; J Dong; Kurt W Kohn; Yves Pommier
Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.
The Journal of biological chemistry 1999;274(40):28246-55.
1999: Dirk Strumberg; John L. Nitiss; A Rose; Marc C Nicklaus; Yves Pommier
Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.
The Journal of biological chemistry 1999;274(11):7292-301.
1998: Yves Pommier; Philippe Pourquier; Y Fan; Dirk Strumberg
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.
Biochimica et biophysica acta 1998;1400(1-3):83-105.
1998: Dirk Strumberg; Jochen Erhard; Andreas Harstrick; U Klaassen; C Müller; Wilfried Eberhardt; Hansjochen Wilke; Siegfried Seeber
Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma.
European journal of cancer (Oxford, England : 1990) 1998;34(8):1290-2.
1998: U Klaassen; Andreas Harstrick; Dirk Strumberg; Hansjochen Wilke; Siegfried Seeber
Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I study.
Anti-cancer drugs 1998;9(4):359-61.
1998: U Klaassen; Hansjochen Wilke; Andreas Harstrick; C Philippou Pari; Dirk Strumberg; K Neumann; Wilfried Eberhardt; Wolf Achterrath; L Lenaz; Siegfried Seeber
Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):45-50.
1997: C Pondarré; Dirk Strumberg; Akira Fujimori; R Torres-León; Yves Pommier
In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Nucleic acids research 1997;25(20):4111-6.
1997: Andreas Harstrick; Claus-Henning Köhne; W Hiddemann; Peter Preusser; Dirk Strumberg; T Berns; S Seeber; Hansjochen Wilke; H J Schmoll
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(9):917-8.
1997: Dirk Strumberg; Andreas Harstrick; U Klaassen; C Müller; Wilfried Eberhardt; MW Korn; Hansjochen Wilke; Siegfried Seeber
Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil.
Anti-cancer drugs 1997;8(3):293-5.
1996: Dirk Strumberg; Andreas Harstrick; K Doll; B Hoffmann; Siegfried Seeber
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Anti-cancer drugs 1996;7(4):415-21.
1996: U Klaassen; Hansjochen Wilke; Dirk Strumberg; Wilfried Eberhardt; MW Korn; Siegfried Seeber
Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A(3):547-9.
1995: U Klaassen; Hansjochen Wilke; C P Pari; Dirk Strumberg; Andreas Harstrick; Wilfried Eberhardt; R Becher; K Diergarten; Siegfried Seeber
Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Seminars in oncology 1995;22(6 Suppl 14):7-11.